Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD of CRISPR Therapeutics AG from 2014 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
CRISPR Therapeutics AG quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and change rate from 2014 to Q3 2025.
  • CRISPR Therapeutics AG Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending September 30, 2025 was -$105M, a 45.5% decline year-over-year.
  • CRISPR Therapeutics AG Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending September 30, 2025 was -$494M, a 122% decline year-over-year.
  • CRISPR Therapeutics AG annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was -$366M, a 169% decline from 2023.
  • CRISPR Therapeutics AG annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$136M, a 79.4% increase from 2022.
  • CRISPR Therapeutics AG annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$661M, a 277% decline from 2021.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)

CRISPR Therapeutics AG Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$494M -$105M -$33M -45.5% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-10
Q2 2025 -$461M -$209M -$80.9M -63.3% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-04
Q1 2025 -$380M -$134M -$13.6M -11.4% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-06
Q4 2024 -$366M -$46M -$144M -147% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-11
Q3 2024 -$222M -$72.5M +$37.5M +34.1% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-10
Q2 2024 -$260M -$128M -$50.5M -65.3% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-04
Q1 2024 -$209M -$120M -$73.3M -156% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-06
Q4 2023 -$136M $98.1M +$202M Oct 1, 2023 Dec 31, 2023 10-K 2025-02-11
Q3 2023 -$338M -$110M +$66.4M +37.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 -$404M -$77.3M +$112M +59.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 -$517M -$46.8M +$144M +75.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$661M -$104M +$41.6M +28.6% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-11
Q3 2022 -$702M -$176M -$49.2M -38.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 -$653M -$189M -$948M -125% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $295M -$191M -$77.5M -68.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $373M -$146M -$38.6M -36% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-21
Q3 2021 $411M -$127M -$34.7M -37.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 $446M $759M +$839M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$393M -$114M -$43.8M -62.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$349M -$107M -$138M -450% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-21
Q3 2020 -$211M -$92.6M -$231M -167% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $19.6M -$79.7M -$26M -48.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 $45.5M -$69.8M -$21.4M -44.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-27
Q4 2019 $66.9M $30.6M +$78.2M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-15
Q3 2019 -$11.3M $138M +$189M Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-28
Q2 2019 -$200M -$53.7M -$15.3M -39.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-27
Q1 2019 -$185M -$48.4M -$20.1M -71.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-04-28
Q4 2018 -$165M -$47.6M -$47.7M -33619% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-16
Q3 2018 -$117M -$50.7M -$26M -105% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-28
Q2 2018 -$91.2M -$38.4M -$16.1M -72.1% Apr 1, 2018 Jun 30, 2018 10-Q 2019-07-29
Q1 2018 -$75.2M -$28.3M -$6.84M -31.9% Jan 1, 2018 Mar 31, 2018 10-Q 2019-04-29
Q4 2017 -$68.3M $142K -$17M -99.2% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-12
Q3 2017 -$51.4M -$24.7M -$10M -68.1% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 -$41.4M -$22.3M -$5.13M -29.9% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 -$36.2M -$21.5M -$13M -154% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 -$23.2M $17.1M Oct 1, 2016 Dec 31, 2016 10-K 2019-02-25
Q3 2016 -$14.7M -$8.34M -131% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 -$17.2M Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-10
Q1 2016 -$8.45M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-11
Q3 2015 -$6.36M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-22

CRISPR Therapeutics AG Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$366M -$230M -169% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-11
2023 -$136M +$525M +79.4% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-11
2022 -$661M -$1.03B -277% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-11
2021 $373M +$722M Jan 1, 2021 Dec 31, 2021 10-K 2024-02-21
2020 -$349M -$416M -622% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-21
2019 $66.9M +$232M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 -$165M -$96.7M -142% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-16
2017 -$68.3M -$45.1M -194% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-12
2016 -$23.2M +$2.61M +10.1% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-25
2015 -$25.8M -$19M -280% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-08
2014 -$6.8M Jan 1, 2014 Dec 31, 2014 10-K 2017-03-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.